INNOVATION WITH TRACTION

You’ll hear how Berkshire Biomedical is building momentum through early pilots and provider partnerships, and how COPA’s™ built-in biometric security, remote configurability, and real-time data make it easy to adopt and scale.

The platform is designed to integrate seamlessly into existing regulatory and reimbursement frameworks, reducing barriers for provider adoption and helping ensure they can get paid for using it.

COUNTDOWN TO WEBINAR

-
Days
-
Hours
-
Minutes
-
Seconds
Learn More about Investing in Berkshire Biomedical

GOING TO MARKET: THE PLAN FOR EXECUTION

We'll highlight how our seasoned team, with an impressive track record of accomplishments, is positioned for success.

THE KEY MILESTONES OF OUR PLAN:

  • FDA filing of COPA™
  • The award of a second NIH grant
  • The start and completion of clinical studies
  • A planned commercial launch backed by additional NIH funding

Meet the Host.

John Timberlake has served as Berkshire Biomedical’s Chief Executive Officer, President, and a member of our Board of Directors since April 2021. Mr. Timberlake has more than 30 years of life sciences experience in bringing pharmaceuticals, medical devices, and drug-device combination products to market.

Featuring Dr. Melissa Olivadoti, Medical Affairs Consultant


Dr. Olivadoti is currently an Independent Medical Affairs Consultant and is assisting Berkshire Biomedical by leading our Medical Affairs activities.  Melissa  has 15+ years’ experience in the pharmaceutical and medical device sectors, having led and supported Medical Affairs functions in emerging and large companies.

Berkshire Biomedical

For investors, this is a chance to see how COPA™ is positioned not just as an innovation, but as a scalable, real-world solution with traction, clarity, and momentum behind it.

Learn How to Invest in Berkshire Biomedical